Table II.

Prognostic factors for progression-free survival.

Prognostic factor	Hazard ratio	95% confidence interval	P-value
Age, <75 vs. ≥75 years	0.82	0.35–1.93	0.64
T stage, T1,2 vs. T3,4	1.63	0.63–4.23	0.32
Gleason score, <8 vs. ≥8	0.95	0.10–2.23	0.90
PSA, <20 vs. ≥20 ng/ml	1.37	0.55–3.41	0.50
Duration of ADT, <36 vs. ≥36 months	0.30	0.12–0.75	0.01
Irradiated volume, PO vs. WP	0.57	0.17–1.87	0.35

PSA, prostate-specific antigen; ADT, androgen deprivation therapy; PO, prostate only; WP, pelvic lymph node and prostate.